title: Captopril prevention project--what shall we do about captopril and the risk of stroke?
authors.forename: A
authors.initials: A
authors.lastname: Fournier
authors.forename: A
authors.initials: A
authors.lastname: Pruna
authors.forename: N E
authors.initials: NE
authors.lastname: Esper
authors.forename: R
authors.initials: R
authors.lastname: Makdassi
authors.forename: R
authors.initials: R
authors.lastname: Oprisiu
authors.forename: P F
authors.initials: PF
authors.lastname: Westeel
authors.forename: H
authors.initials: H
authors.lastname: Mazouz
authors.forename: J M
authors.initials: JM
authors.lastname: Achard
mesh_terms: D000804:Angiotensin II / Q000494:pharmacology; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use; D002545:Brain Ischemia / Q000517:prevention & control; D002216:Captopril / Q000494:pharmacology*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D020521:Stroke / Q000517:prevention & control*
chemical_list: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D000804:Angiotensin II; D002216:Captopril